Literature DB >> 32767367

Impact of asymptomatic COVID-19 patients in global surgical practice during the COVID-19 pandemic.

V Bellato1, T Konishi2, G Pellino3,4, Y An5, A Piciocchi6, B Sensi1, L Siragusa1, K Khanna7, B M Pirozzi1, M Franceschilli1, M Campanelli1, S Efetov8, G S Sica1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32767367      PMCID: PMC7929295          DOI: 10.1002/bjs.11800

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


× No keyword cloud information.
Editor The rapid spread of COVID-19 has changed the global surgical care. Patients infected with COVID-19 may present without typical symptoms, and such asymptomatic patients may potentially trigger in-hospital outbreaks by transmitting the disease to health care providers and other hospitalized patients[4,5]. Further, asymptomatic COVID-19 patients have worse postoperative outcomes with an unexpectedly high morbidity and mortality, reaching 20·5 per cent deaths. However, we do not have objective global data on this issue. In an attempt to clarify the current global surgical practice under the COVID-19 pandemic particularly focusing on the preoperative screening of asymptomatic COVID-19 patients, we conducted a cross-sectional online survey on surgical practice. The survey was administered to surgeons worldwide through international surgical societies, social media and personal contacts during 2 April to 8 April. The results were analyzed by country's cumulative deaths number by 8 April, 2020 (high risk, >5000; intermediate risk, 100-5000; low risk, <100) (https://covid19.who.int/). The survey was completed by a total of 936 centres in 71 countries, involving 5 high risk countries (330 centres), 20 intermediate risk countries (242 centres) and 46 low risk countries (364 centres). Table 1 summarizes the results of the survey. The majority (73·8 per cent) of the centers performed preoperative COVID-19 testing based on symptoms or suspicious radiologic findings. Universal COVID-19 testing for every patient was performed in only 16·6 per cent of the centers, and the proportion was less than 30 per cent even in severely affected countries. Asymptomatic COVID-19 patients who tested positive postoperatively were reported from 27·5 per cent of the centres, with higher rates in higher risk countries (high risk, 51·5 per cent; intermediate risk, 27·3 per cent; low risk, 5·8 per cent; p < 0·001). To further clarify the clinical impact of asymptomatic COVID-19 patients, the second survey was sent to 218 centres that experienced such patients and had contact information, and 149 responded. The median number of asymptomatic COVID-19 patients testing positive after surgery per centre was 2 (range, 1 to 20). After experiencing the first asymptomatic COVID-19 patients, most centers (81·9 per cent) changed testing policies and/or preventive measures in surgical practice. Worse surgical outcomes in asymptomatic COVID-19 patients were reported from 30·9 per cent of the centres.
Table 1

Preoperatively asymptomatic COVID-19 patients by the countries' risk group

  Countries by risk group
OverallHigh riskInt. riskLow risk 
 936330242364 P Value
Testing policies before surgery. No. (%) a      
  Everyone155 (16·6)91 (27·6)43 (17·8)21 (5·8)<·001
  All oncologic patients42 (4·5)24 (7·3)14 (5·8)4 (1·1)<·001
  All emergency patients73 (7·8)41 (12·4)22 (9·1)10 (2·7)<·001
  Symptomatic or suspicious radiological features691 (73·8)214 (64·8)183 (75·6)294 (80·8) ·03
Experienced preoperatively asymptomatic patients tested positive after surgery. No. (%)      
  Yes257 (27·5)170 (51·5)66 (27·3)21 (5·8)<·001
  No679 (72·5)160 (48·5)176 (72·7)343 (94·2) 
Experienced preoperatively asymptomatic patients tested positive after surgery with symptoms. No. (%)      
  Yes231 (24·7)158 (47·9)55 (22·7)18 (4·9)<·001
  No705 (75·3)172 (52·1)187 (77·3)346 (95·1) 
Experienced preoperatively asymptomatic patients tested positive after surgery without symptoms. No. (%)      
  Yes157 (16·8)108 (32·7)39 (16·1)10 (2·7)<·001
  No779 (83·2)222 (67·3)203 (83·9)354 (97·3) 
Preventive measures changed due to the asymptomatic patients? (2nd survey) No. (%) [a, b]      
  Yes, PPE use40 (26·8)    
  Yes, PPE availability23 (15·4)    
  Yes, preoperative patient testing55 (36·9)    
  Yes, staff testing26 (17·4)    
  Yes, staff rotation16 (10·7)    
  Yes, COVID-19 dedicated area54 (36·2)    
  Yes, stop elective surgeries31 (20·8)    
  No27 (18·1)    
Did you observe a worse surgical outcome related to asymptomatic COVID-19 patient? (2nd survey) No. (%) b      
  Yes46 (30·9)    
  No/I don't know103 (69·1)    

Int: intermediate.

Percentages do not add up to 100 because of the multiple choice question.

The second survey respondents are the centers that answered ‘yes’ in the question ‘Experienced preoperatively asymptomatic patients tested positive after surgery’ (n = 149). The data are not analyzed by countries' risk group.

Preoperatively asymptomatic COVID-19 patients by the countries' risk group Int: intermediate. Percentages do not add up to 100 because of the multiple choice question. The second survey respondents are the centers that answered ‘yes’ in the question ‘Experienced preoperatively asymptomatic patients tested positive after surgery’ (n = 149). The data are not analyzed by countries' risk group. To our knowledge, this is one of the largest international surveys on COVID-19 in the field of surgery. Acknowledging the biases caused by unintended selection of centres, unequal number of centres per country and uneven geographical coverage, this large survey captured the global surgical practice under the COVID-19 pandemic and highlighted the threat of asymptomatic patients. Asymptomatic COVID-19 patients who were tested positive postoperatively may represent insufficient preoperative screening in the current surgical practice. The clinical impact of asymptomatic COVID-19 patients for surgeons is evident by the fact that the detection of such asymptomatic patients resulted in the change of testing policies and/or preventive measures in most of the centres. We strongly believe that in the coming phase of pandemic, during which many medical centres will resume elective surgeries, a call for action in surgical departments for more intensive screening programs is needed in global plans. Appendix Contributors Click here for additional data file.
  6 in total

Review 1.  Safe management of surgical smoke in the age of COVID-19.

Authors:  N G Mowbray; J Ansell; J Horwood; J Cornish; P Rizkallah; A Parker; P Wall; A Spinelli; J Torkington
Journal:  Br J Surg       Date:  2020-05-03       Impact factor: 6.939

Review 2.  Recommendations for general surgery activities in a pandemic scenario (SARS-CoV-2).

Authors:  F Di Marzo; M Sartelli; R Cennamo; G Toccafondi; F Coccolini; G La Torre; G Tulli; M Lombardi; M Cardi
Journal:  Br J Surg       Date:  2020-04-23       Impact factor: 6.939

Review 3.  Immediate and long-term impact of the COVID-19 pandemic on delivery of surgical services.

Authors:  K Søreide; J Hallet; J B Matthews; A A Schnitzbauer; P D Line; P B S Lai; J Otero; D Callegaro; S G Warner; N N Baxter; C S C Teh; J Ng-Kamstra; J G Meara; L Hagander; L Lorenzon
Journal:  Br J Surg       Date:  2020-04-30       Impact factor: 6.939

4.  COVID-19 pandemic: perspectives on an unfolding crisis.

Authors:  A Spinelli; G Pellino
Journal:  Br J Surg       Date:  2020-03-23       Impact factor: 6.939

Review 5.  Global guidance for surgical care during the COVID-19 pandemic.

Authors: 
Journal:  Br J Surg       Date:  2020-04-15       Impact factor: 6.939

6.  Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection.

Authors:  Shaoqing Lei; Fang Jiang; Wating Su; Chang Chen; Jingli Chen; Wei Mei; Li-Ying Zhan; Yifan Jia; Liangqing Zhang; Danyong Liu; Zhong-Yuan Xia; Zhengyuan Xia
Journal:  EClinicalMedicine       Date:  2020-04-05
  6 in total
  7 in total

1.  Sclerotherapy for III- and IV-degree hemorrhoids: Results of a prospective study.

Authors:  Giorgio Lisi; Paolo Gentileschi; Domenico Spoletini; Umberto Passaro; Simone Orlandi; Michela Campanelli
Journal:  Front Surg       Date:  2022-09-01

Review 2.  Influence of the COVID-19 pandemic in the gastrointestinal oncology setting: An overview.

Authors:  Breno Bittencourt de Brito; Hanna Santos Marques; Filipe Antônio França da Silva; Maria Luísa Cordeiro Santos; Glauber Rocha Lima Araújo; Lara de Araujo Valente; Fabrício Freire de Melo
Journal:  World J Gastrointest Pathophysiol       Date:  2022-09-22

3.  Surgeons' fear of getting infected by COVID19: A global survey.

Authors:  Yongbo An; Vittoria Bellato; Tsuyoshi Konishi; Gianluca Pellino; Bruno Sensi; Leandro Siragusa; Marzia Franceschilli; Giuseppe S Sica
Journal:  Br J Surg       Date:  2020-08-18       Impact factor: 6.939

4.  Screening policies, preventive measures and in-hospital infection of COVID-19 in global surgical practices.

Authors:  Vittoria Bellato; Tsuyoshi Konishi; Gianluca Pellino; Yongbo An; Alfonso Piciocchi; Bruno Sensi; Leandro Siragusa; Krishn Khanna; Brunella Maria Pirozzi; Marzia Franceschilli; Michela Campanelli; Sergey Efetov; Giuseppe S Sica
Journal:  J Glob Health       Date:  2020-12       Impact factor: 4.413

5.  Feasibility and outcomes of ERAS protocol in elective cT4 colorectal cancer patients: results from a single-center retrospective cohort study.

Authors:  Vittoria Bellato; Yongbo An; Daniele Cerbo; Michela Campanelli; Marzia Franceschilli; Krishn Khanna; Bruno Sensi; Leandro Siragusa; Piero Rossi; Giuseppe S Sica
Journal:  World J Surg Oncol       Date:  2021-07-02       Impact factor: 2.754

6.  The Relationship between the Infertility Specialist and the Patient during the COVID-19 Pandemic.

Authors:  Diana Antonia Iordăchescu; Florinda Tinella Golu; Corina Ioana Paica; Adrian Gorbănescu; Anca Maria Panaitescu; Corina Gică; Gheorghe Peltecu; Nicolae Gică
Journal:  Healthcare (Basel)       Date:  2021-11-28

7.  Disease Prevalence Matters: Challenge for SARS-CoV-2 Testing.

Authors:  Chin-Shern Lau; Tar-Choon Aw
Journal:  Antibodies (Basel)       Date:  2021-12-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.